SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing massive momentum as investors bet on the company's critical role in the AI-driven memory chip supercycle, with community chatter centered on explosive demand for High Bandwidth Memory and a dramatic market rerating. While bullish participants highlight the stock's long-term growth potential and structural supply tightness, others are debating whether the current parabolic price action suggests an overextended market or the early stages of a historic cycle.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending heavily as the market reacts to reports that FDA Commissioner Marty Makary will be fired, a move seen by the community as a major potential catalyst for removing bureaucratic hurdles to the company's drug pipeline. Investors are closely monitoring for official FDA regulatory updates while discussing aggressive call option activity and the company's global expansion efforts as indicators of imminent positive momentum.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high-intensity trading and community debate as investors navigate recent FCC regulatory approvals alongside skepticism regarding satellite deployment timelines. Bulls are betting on a massive short squeeze and long-term potential in direct-to-device connectivity, while bears remain focused on execution risks and past missed targets ahead of the upcoming earnings report.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are aggressively debating the sustainability of the semiconductor sector's parabolic rally, with many viewing the current price action as an unsustainable bubble driven by FOMO and AI-related hype. Community sentiment is deeply polarized, characterized by 'bagholders' bracing for a potential historic correction while short-sellers struggle against the heavy daily decay and relentless dip-buying that keeps the sector pinned at historical highs.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is attracting significant investor attention following a confirmed billion-dollar colocation contract with Cerebras Systems, which the community views as a major valuation catalyst leading into the upcoming Cerebras IPO. While traders are actively debating the potential impact of share offerings on near-term price action, many remain bullish, framing the stock as an undervalued AI infrastructure play compared to its sector peers.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing a massive rally following a record-breaking earnings report and new, high-value launch contracts that have solidified its standing in the space infrastructure sector. The community is actively discussing the stock's aggressive momentum and price discovery, with many debating the impact of upcoming sector-wide catalysts and the potential for long-term repricing as the company secures key defense and commercial backlog growth.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as investors react to a challenging earnings report and critical comments from the CEO regarding weakened consumer spending. The stock faces heavy selling pressure as community members actively debate the company's leadership, the impact of rising costs on their core demographic, and whether the recent sell-off represents a buying opportunity.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing heightened investor scrutiny as traders debate whether its recent earnings beat and strong market share growth justify a recovery from 52-week lows or if broader sector competition and margin concerns will continue to fuel volatility. The community remains deeply divided, with many citing the stock's significant price disconnect as an opportunity to accumulate, while others express frustration over institutional selling and concerns regarding long-term brand durability.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive gains driven by an intense AI-induced supply shortage of NAND flash memory, which has spurred significant bullish sentiment and speculation about continued parabolic growth. While the community is actively debating the stock's astronomical rally and comparing it to historic bubbles, many investors are focused on the long-term structural demand in the AI data center sector.

Kopin Corp. engages in the development, manufacture and sale of wearable technologies which include components and systems. Its portfolio includes AMLCD, LCOS displays, OLED displays, ASIC, backlights, and optical lenses. The firm uses semiconductor material technology to design, manufacture and market its component products for use in military, enterprise and consumer electronic applications, training and simulation equipment and 3D metrology equipment. The company was founded by John C.C. Fan on April 23, 1984 and is headquartered in Westborough, MA.

Kopin Corp.

Kopin Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Odyssey Therapeutics stated that it had also raised an additional $25 million through a private placement of 1.39 million shares of its common stock to an affiliate of TPG Life Sciences Innovations.</li><li>Odyssey plans to use the proceeds of the offering and private placement to advance the development of OD-001, its most advanced drug candidate for the treatment of ulcerative colitis and Crohn’s disease.</li><li>It also disclosed plans to advance its SLC15A4 program and to fund additional discovery, preclinical, and clinical activities for disclosed or future programs.</li></ul>Shares of Odyssey Therapeutics Inc. (ODTX) gained nearly 13% in its debut on the Nasdaq on Friday, reaching a valuation of $900 million as equity markets hover near new all-time highs.<a href="https://stocktwits.com/symbol/ODTX">Odyssey Therapeutics shares</a> debuted on the Nasdaq at $20. However, the stock has lost all its gains at the time of writing, trading nearly 10% lower at $16 per share, compared to its issue price of $18 per share.The Boston-based clinical-stage biopharmaceutical company raised $279 million through an upsized offering, issuing 15.5 million shares of its common stock. The company also stated that the underwriters have an option to purchase up to an additional 2.33 million shares within 30 days from the date of issue.Retail sentiment on Stocktwits around Odyssey Therapeutics trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">ODTX Raises Additional $25M From Private Placement</h2>Odyssey Therapeutics stated that it had also raised an additional $25 million through a private placement of 1.39 million shares of its common stock to an affiliate of TPG Life Sciences Innovations at the IPO price of $18 per share.Overall, Odyssey’s gross proceeds from the public issue and the private placement stood at $304 million.The company had previously filed for an IPO in 2025, but withdrew it a few months later.Odyssey plans to use the proceeds of the offering and private placement to advance the development of OD-001, its most advanced drug candidate for the treatment of ulcerative colitis and Crohn’s disease. It also disclosed plans to advance its SLC15A4 program and to fund additional discovery, preclinical, and clinical activities for disclosed or future programs.<h2 class="st-heading-2">What Does ODTX Do?</h2>Odyssey Therapeutics is a clinical-stage biotech company developing targeted treatments for autoimmune and inflammatory diseases.Founded in 2021, the company has built an internally developed pipeline of drug candidates that precisely target disease pathways and deliver deeper, longer-lasting remission for patients with unmet medical needs.According to the company’s filings with the U.S. Securities and Exchange Commission (SEC), Odyssey reported a net loss of $148.6 million in 2025, while its net loss for 2024 stood at $129.3 million.Odyssey stated that it had $175.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026.The Renaissance IPO ETF (IPO) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/groupon-missed-q1-estimates-why-is-grpn-stock-soaring-today/cZX28P9Reg7">GRPN Stock Heads For Best Day In A Year Despite Earnings Miss — Here’s Why CEO Senkypl Is Confident About ‘Stronger Performance Ahead’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an IPO (Initial public offering) words are seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

The Boston-based clinical-stage biopharmaceutical company raised $279 million through an upsized offering, issuing 15.5 million shares of its common stock.

Equity

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system for patients suffering from autoimmune and inflammatory diseases. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

Odyssey Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$16.42
Prev Close	$18.00
Open	$20.00
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

ODTX
Odyssey Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ODTX News

ODTXOdyssey Therapeutics Inc